A Firsthand Look at the ExtendMed Advantage
With a wide range of promotional and CME programs, ExtendMed has become a leading name in medical education. Here you can access a sampling of our recent programs. Please note that the programs marked CME are complete, fully-accredited courses available for medical certification.
Mastering Valuable Hands On Procedures
Family physicians, FNPs and PAs often see patients with conditions that require the performance of a minor office procedure. Too often, many patients are referred out of the practice. Learn the benefits of adding these simple procedures to your practice. This CME online program will demonstrate the indications and contraindications for joint and soft-tissue injections and aspirations. Also the program will address the common techniques used to perform skin biopsies.
ASGE Online Learning Center
This site includes online educational activities such as Clinical Guidelines CME, videos from the Endoscopic Learning Library (previously only available on DVD), and additional recorded sessions, practice management resources and Video Forum selections. You can search for these activities by type of activity, topic, or keywords.
SCOPE of Pain: Safe and Competent Opioid Prescribing Education
7644 registrants. 4112 have completed the program.
SCOPE of pain is an educational program that will help you safely and competently manage your patients with chronic pain. Through the case of Mary Williams, a 42 year old with painful diabetic neuropathy and chronic low back pain, you'll learn how to: 1) decide on appropriateness of opioid analgesics; 2) assess for opioid misuse risk; 3) counsel patients about opioid safety, risks and benefits; 4) competently monitor patients prescribed opioids for benefit and harm; 5) make decisions on continuing or discontinuing opioid analgesics; 6) safely discontinue opioids when there is too little benefit or too much risk and harm. Offered in collaboration with the Council of Medical Specialty Societies (CMSS) and the Federation of State Medical Boards (FSMB), this program addresses the FDA mandate to manufacturers of extended release/long-acting (ER/LA) opioid analgesics, by providing comprehensive prescriber education in the safe use of these medications. It also addresses many key elements of the physician education component of the Obama Administration's prescription drug abuse prevention plan on prescriber education released in April 2011. This program is funded by an unrestricted educational grant awarded by the manufacturers of ER/LA opioid analgesics, known as the REMS Program Companies (RPC).
Symptomatic Vulvovaginal Atrophy: Breaking Down Barriers to Identification and Treatment
574 registrants. 121 have completed the program.
Approximately 50% of all menopausal women experience symptoms of vulvovaginal atrophy (VVA), a condition that often manifests in distressing symptoms, including dryness, irritation, burning, itching, recurrent vaginitis, and painful intercourse, as well as increased risk for recurrent urinary tract infections and incontinence. While the vasomotor symptoms of menopause resolve completely with or without treatment in most cases, VVA rarely improves without intervention. In its updated, 2013 position statement, The North American Menopause Society (NAMS) recommended that health care providers raise the topic of VVA with all perimenopausal and postmenopausal women as part of the routine review of systems. Unfortunately, affected women are frequently reluctant to discuss sensitive topics like vaginal health and sexual dysfunction with their health care providers, and many are unaware that safe, effective treatments for VVA exist.
Exploring the Management and Treatment of Anaphylaxis
322 registrants. 112 have completed the program.
Up to 6 million people in the US are at risk for anaphylaxis. Multiple studies and surveys show increasing prevalence of anaphylaxis, particularly among those under age 20. This program provides an overview of diagnosis and treatment of anaphylaxis. There will also be an exploration of the features and use of Auvi-Q (epinephrine injection, USP), an epinephrine auto-injector that was introduced this year.
Prophylaxis in Hemophilia: Towards a World Without Bleeds
For some patients with hemophilia, bleeding is viewed as a normal and acceptable consequence of their coagulopathy. Yet even 2 hemarthroses annually can cause structural joint damage that results in deteriorating joint function.Prophylaxis is key to changing patient expectations about bleeding. Although prophylaxis cannot reverse existing arthropathy, it can transform a severe bleeding phenotype into a milder one. This transformation slows joint deterioration, decreases the frequency of bleeding episodes, improves mobility and health-related quality of life, and reduces work absences and hospitalizations. Two prospective, randomized clinical trials have shown that FEIBA prophylaxis can extend the benefits of prophylactic therapy to hemophilia patients with inhibitors. In the 1-year, open-label, parallel arm PROOF study, bleeding episodes were significantly lower in inhibitor patients randomized to every other day FEIBA prophylaxis compared with those treated on-demand for acute bleeding with FEIBA. These findings support earlier results from the 6-month, crossover Pro-FEIBA study, in which FEIBA prophylaxis significantly reduced all bleeding episodes, hemarthroses, and target joint bleeding.